AU2001267371B2 - Stabilized aqueous suspensions for parenteral use - Google Patents

Stabilized aqueous suspensions for parenteral use Download PDF

Info

Publication number
AU2001267371B2
AU2001267371B2 AU2001267371A AU2001267371A AU2001267371B2 AU 2001267371 B2 AU2001267371 B2 AU 2001267371B2 AU 2001267371 A AU2001267371 A AU 2001267371A AU 2001267371 A AU2001267371 A AU 2001267371A AU 2001267371 B2 AU2001267371 B2 AU 2001267371B2
Authority
AU
Australia
Prior art keywords
formulation according
concentration
formulation
biologically active
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2001267371A
Other languages
English (en)
Other versions
AU2001267371A1 (en
Inventor
Giuseppe Colombo
Lloyd E. Fox
Alessandro Martini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co LLC
Original Assignee
Pfizer Italia SRL
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Italia SRL, Pharmacia and Upjohn Co LLC filed Critical Pfizer Italia SRL
Publication of AU2001267371A1 publication Critical patent/AU2001267371A1/en
Application granted granted Critical
Publication of AU2001267371B2 publication Critical patent/AU2001267371B2/en
Assigned to PHARMACIA AND UPJOHN COMPANY LLC, PFIZER ITALIA S.R.L. reassignment PHARMACIA AND UPJOHN COMPANY LLC Request for Assignment Assignors: PHARMACIA AND UPJOHN COMPANY LLC, PHARMACIA ITALIA S.P.A.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001267371A 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use Expired AU2001267371B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/571,395 2000-05-15
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use
PCT/EP2001/004643 WO2001087266A1 (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use

Publications (2)

Publication Number Publication Date
AU2001267371A1 AU2001267371A1 (en) 2002-02-14
AU2001267371B2 true AU2001267371B2 (en) 2006-01-05

Family

ID=24283530

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001267371A Expired AU2001267371B2 (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use
AU6737101A Pending AU6737101A (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU6737101A Pending AU6737101A (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use

Country Status (30)

Country Link
US (3) US6495534B2 (enExample)
EP (1) EP1282402B1 (enExample)
JP (1) JP4205341B2 (enExample)
KR (1) KR100828957B1 (enExample)
CN (1) CN100473376C (enExample)
AR (3) AR029924A1 (enExample)
AT (1) ATE313316T1 (enExample)
AU (2) AU2001267371B2 (enExample)
BR (1) BR0110841A (enExample)
CA (1) CA2409059C (enExample)
CZ (1) CZ303872B6 (enExample)
DE (1) DE60116084T2 (enExample)
DK (1) DK1282402T3 (enExample)
EA (1) EA007682B1 (enExample)
EE (1) EE05376B1 (enExample)
ES (1) ES2254443T3 (enExample)
HK (1) HK1054194B (enExample)
HU (1) HU229800B1 (enExample)
IL (2) IL152537A (enExample)
IN (1) IN224279B (enExample)
MX (1) MXPA02011195A (enExample)
NO (1) NO332215B1 (enExample)
NZ (1) NZ522324A (enExample)
PE (1) PE20011322A1 (enExample)
PL (1) PL203075B1 (enExample)
SI (1) SI1282402T1 (enExample)
SK (1) SK287641B6 (enExample)
TW (1) TWI256310B (enExample)
WO (1) WO2001087266A1 (enExample)
ZA (1) ZA200208738B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
AU2003265511A1 (en) 2002-08-21 2004-03-11 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
WO2004043375A2 (en) * 2002-11-08 2004-05-27 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
DE602004015755D1 (de) * 2003-03-31 2008-09-25 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
KR101288265B1 (ko) * 2003-09-03 2013-07-26 미스콘 트레이딩 에스.에이. 자궁 내막증의 치료 방법
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
CA2581076A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
US20060204588A1 (en) * 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
US20070191323A1 (en) * 2006-02-15 2007-08-16 Verus Pharmaceuticals, Inc. Stable corticosteroid mixtures
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
US7589106B2 (en) * 2006-09-27 2009-09-15 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
CA2697160A1 (en) * 2007-08-21 2009-02-26 Harbor Biosciences, Inc. Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
AU2012273121B2 (en) 2011-06-19 2016-08-25 Abogen, Inc. Devices, solutions and methods for sample collection
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9649353B2 (en) 2013-09-17 2017-05-16 Terapio Corporation Methods of preventing or treating mucositis by administering RLIP76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US9265396B1 (en) 2015-03-16 2016-02-23 Irobot Corporation Autonomous floor cleaning with removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US11135154B2 (en) 2016-03-02 2021-10-05 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
US11141384B2 (en) 2017-07-14 2021-10-12 Janssen Pharmaceutica Nv Long-acting formulations
WO2019048906A1 (en) * 2017-09-07 2019-03-14 Teva Pharmaceutical Industries Ltd. INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE
US20200281939A1 (en) * 2017-09-07 2020-09-10 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
MX2020004792A (es) 2017-11-08 2020-08-13 Eagle Pharmaceuticals Inc Formulaciones de fulvestrant y metodos de su uso.
IL275394B2 (en) 2018-01-11 2024-11-01 Meritage Pharma Inc Stable corticosteroid compositions
WO2020049521A1 (en) * 2018-09-07 2020-03-12 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
AU2019384801A1 (en) 2018-11-20 2021-06-10 Spectrum Solutions, Llc Sample collection system including sealing cap and valve
IT201900002857A1 (it) 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
EP4090353A4 (en) 2020-01-13 2023-08-09 Durect Corporation DELAYED-RELEASE DRUG DELIVERY SYSTEMS WITH REDUCED IMPURITIES AND RELATED PROCEDURES
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022245939A1 (en) * 2021-05-19 2022-11-24 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569464A (en) * 1993-04-02 1996-10-29 Wakamoto Pharmaceutical Co., Ltd. Stable aqueous dispersions containing liposomes
WO1998011912A1 (en) * 1996-09-20 1998-03-26 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
AU9627698A (en) * 1997-09-23 1999-04-12 Rentschler Biotechnologie Gmbh Liquid interferon-beta formulations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
ES2062310T3 (es) 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
WO1998014476A1 (en) 1996-10-04 1998-04-09 Amgen Inc. Pharmaceutical compositions containing an mpl ligand
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
ES2212550T3 (es) 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
ATE464062T1 (de) 1999-10-04 2010-04-15 Novartis Vaccines & Diagnostic Stabilisierte flüssige pharmazeutische zusammensetzung enthaltend tfpi
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569464A (en) * 1993-04-02 1996-10-29 Wakamoto Pharmaceutical Co., Ltd. Stable aqueous dispersions containing liposomes
WO1998011912A1 (en) * 1996-09-20 1998-03-26 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
AU9627698A (en) * 1997-09-23 1999-04-12 Rentschler Biotechnologie Gmbh Liquid interferon-beta formulations

Also Published As

Publication number Publication date
IL165888A0 (en) 2006-01-15
SI1282402T1 (sl) 2006-04-30
ZA200208738B (en) 2003-10-29
JP2003533467A (ja) 2003-11-11
NO20025431D0 (no) 2002-11-13
ATE313316T1 (de) 2006-01-15
CN1429101A (zh) 2003-07-09
KR100828957B1 (ko) 2008-05-13
EP1282402A1 (en) 2003-02-12
KR20030020280A (ko) 2003-03-08
DK1282402T3 (da) 2006-05-08
CZ303872B6 (cs) 2013-06-05
AR029924A1 (es) 2003-07-23
NZ522324A (en) 2005-02-25
AR111695A2 (es) 2019-08-07
TWI256310B (en) 2006-06-11
AU6737101A (en) 2001-11-26
HK1054194A1 (zh) 2003-11-21
PE20011322A1 (es) 2002-01-10
US20030130245A1 (en) 2003-07-10
BR0110841A (pt) 2003-03-11
CN100473376C (zh) 2009-04-01
AR098830A2 (es) 2016-06-15
EP1282402B1 (en) 2005-12-21
US20020115645A1 (en) 2002-08-22
JP4205341B2 (ja) 2009-01-07
EE05376B1 (et) 2011-02-15
IL152537A0 (en) 2003-05-29
HUP0302021A2 (hu) 2003-09-29
CA2409059A1 (en) 2001-11-22
HK1054194B (zh) 2010-02-12
US6495534B2 (en) 2002-12-17
HUP0302021A3 (en) 2011-03-28
ES2254443T3 (es) 2006-06-16
SK287641B6 (sk) 2011-05-06
IL152537A (en) 2007-06-17
DE60116084T2 (de) 2006-08-17
EA200201208A1 (ru) 2003-04-24
EE200200631A (et) 2004-04-15
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
NO20025431L (no) 2003-01-13
MXPA02011195A (es) 2003-03-10
CA2409059C (en) 2006-04-18
WO2001087266A1 (en) 2001-11-22
EA007682B1 (ru) 2006-12-29
PL365793A1 (en) 2005-01-10
HU229800B1 (en) 2014-07-28
SK15982002A3 (sk) 2003-05-02
IN224279B (enExample) 2005-02-25
NO332215B1 (no) 2012-07-30
PL203075B1 (pl) 2009-08-31
US20030114430A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
AU2001267371B2 (en) Stabilized aqueous suspensions for parenteral use
AU2001267371A1 (en) Stabilized aqueous suspensions for parenteral use
KR101053780B1 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
TWI772659B (zh) 醫藥配方
US12138271B2 (en) Pharmaceutical compositions of testosterone
KR101924786B1 (ko) 이부프로펜의 주사용 약제학적 조성물
US20030165568A1 (en) Stabilized steroidal suspension
EP4192428A1 (en) Phytonadione compositions
CN101155584A (zh) 给药伊沙匹隆的方法
EP4076442A1 (en) Pharmaceutical composition of cyclooxygenase - 2 inhibitors
EP4551298A1 (en) Stable, liquid pharmaceutical compositions comprising melphalan
US20150141518A1 (en) Water-miscible stable solution composition for pharmaceutically active ingredients that are poorly soluble in water and susceptible to chemical degradation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PHARMACIA AND UPJOHN COMPANY LLC; PFIZER ITALIA S.

Free format text: FORMER OWNER WAS: PHARMACIA ITALIA S.P.A.; PHARMACIA AND UPJOHN COMPANY LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired